Literature DB >> 7768252

Debrisoquine hydroxylation in a Polish population.

P K Kunicki1, D Sitkiewicz, A Pawlik, V Bielicka-Sulzyc, E Borowiecka, B Gawrońska-Szklarz, R Sterna, H Matsumoto, M Radziwoń-Zaleska.   

Abstract

The genetic polymorphism of drug oxidation mediated by cytochrome P450IID6 (CYP2D6) was determined in 154 Polish volunteers using debrisoquine as the test substance. The results showed a bimodal distribution of the debrisoquine metabolic ratio (MR). Nine persons (5.8%) with MR > 12.6 were classified as poor metabolisers (gene frequency 0.242), which is in substantial agreement with the data reported for other Caucasian populations.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7768252     DOI： 10.1007/BF00193702

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


  19 in total

1.  N-acetylation and debrisoquine type oxidation polymorphism in Caucasians--with reference to age and sex.

Authors:  W Siegmund; W Hanke; M Zschiesche; G Franke; K E Biebler; A Wilke
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1990-12

Review 2.  Interethnic variation of drug metabolism.

Authors:  W Kalow
Journal:  Trends Pharmacol Sci       Date:  1991-03       Impact factor: 14.819

3.  Polymorphism of debrisoquine oxidation in New Zealand Caucasians.

Authors:  S Wanwimolruk; J R Denton; D G Ferry; M Beasley; J R Broughton
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

4.  Genetically determined sparteine oxidation polymorphism in a Polish population.

Authors:  K Orzechowska-Juzwenko; J Pawlik; P Niewiński; P Milejski; J Dembowski; J Turek; A Goździk; L Swiebodzki; Z Hora
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

5.  Polymorphic hydroxylation of debrisoquine.

Authors:  G T Tucker; J H Silas; A O Iyun; M S Lennard; A J Smith
Journal:  Lancet       Date:  1977-10-01       Impact factor: 79.321

6.  Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations.

Authors:  G Alván; P Bechtel; L Iselius; U Gundert-Remy
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

7.  Debrisoquine oxidation polymorphism: phenotypic consequences of a 3-base-pair deletion in exon 5 of the CYP2D6 gene.

Authors:  F Broly; U A Meyer
Journal:  Pharmacogenetics       Date:  1993-06

8.  Comparison of gas chromatographic and high-performance liquid chromatographic assays for the determination of debrisoquine and its 4-hydroxy metabolite in human fluids.

Authors:  K Chan
Journal:  J Chromatogr       Date:  1988-03-18

Review 9.  Clinical consequences of polymorphic drug oxidation.

Authors:  G Alván
Journal:  Fundam Clin Pharmacol       Date:  1991       Impact factor: 2.748

10.  The metabolism of debrisoquine in man: (1) regioselectivity of hydroxylation and (2) aberrant oxidative metabolism in two sibling patients with carbimazole-induced agranulocytosis.

Authors:  J C Ritchie; M J Crothers; R R Shah; J R Idle; R L Smith
Journal:  Xenobiotica       Date:  1986-05       Impact factor: 1.908
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.